|
Burden of surgeries and surgical complications in patients with Von Hippel Lindau (VHL) disease before and after treatment with belzutifan. |
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
Employment - Analysis Group |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
|
Stock and Other Ownership Interests - Merck |
|
|
Employment - Analysis Group |
|
|
Employment - Analysis Group |
|
|
Employment - Analysis Group |
|
|
Consulting or Advisory Role - aravive; Aveo; Calithera Biosciences; Eisai; Exelixis; Merck; NiKang Therapeutics; Novartis; Pfizer; Takeda |
Research Funding - Arrowhead Pharmaceuticals (Inst); Merck; NiKang Therapeutics; Novartis |
Travel, Accommodations, Expenses - Pfizer |